1 Sumida, Y. & Yoneda, M. Current and future pharmacological therapies for NAFLD/NASH. Journal of gastroenterology53, 362-376 (2018).
2 Stefan, N., Häring, H.-U. & Cusi, K. Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies. The lancet Diabetes & endocrinology7, 313-324 (2019).
3 Younossi, Z. M. et al. Global epidemiology of nonalcoholic fatty liver disease—meta‐analytic assessment of prevalence, incidence, and outcomes. Hepatology64, 73-84 (2016).
4 Eguchi, Y. et al. Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2009 to 2010 in Japan: a multicenter large retrospective study. Journal of gastroenterology47, 586-595 (2012).
5 Pais, R. et al. NAFLD and liver transplantation: current burden and expected challenges. Journal of hepatology65, 1245-1257 (2016).
6 Yoshitaka, H. et al. Nonoverweight nonalcoholic fatty liver disease and incident cardiovascular disease: a post hoc analysis of a cohort study. Medicine96 (2017).
7 Brouwers, M. C., Simons, N., Stehouwer, C. D. & Isaacs, A. Non-Alcoholic fatty liver disease and cardiovascular disease: assessing the evidence for causality. Diabetologia, 1-8 (2020).
8 Kotronen, A. & Yki-Järvinen, H. Fatty liver: a novel component of the metabolic syndrome. Arteriosclerosis, thrombosis, and vascular biology28, 27-38 (2008).
9 Targher, G., Day, C. P. & Bonora, E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. New England Journal of Medicine363, 1341-1350 (2010).
10 Anstee, Q. M., Targher, G. & Day, C. P. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nature reviews Gastroenterology & hepatology10, 330 (2013).
11 Lonardo, A., Ballestri, S., Marchesini, G., Angulo, P. & Loria, P. Nonalcoholic fatty liver disease: a precursor of the metabolic syndrome. Digestive and Liver disease47, 181-190 (2015).
12 Neuschwander‐Tetri, B. A. et al. Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease. Hepatology52, 913-924 (2010).
13 Kaps, L. et al. Non-alcoholic fatty liver disease increases the risk of incident chronic kidney disease. United European Gastroenterology Journal, 2050640620944098 (2020).
14 Armstrong, M. J., Adams, L. A., Canbay, A. & Syn, W. K. Extrahepatic complications of nonalcoholic fatty liver disease. Hepatology59, 1174-1197 (2014).
15 Estep, J., Birerdinc, A. & Younossi, Z. Non-invasive diagnostic tests for non-alcoholic fatty liver disease. Current molecular medicine10, 166-172 (2010).
16 Hemani, G. et al. The MR-Base platform supports systematic causal inference across the human phenome.(Clinical report). eLife7, doi:10.7554/eLife.34408 (2018).
17 Mohammadi-Shemirani, P. et al. A Mendelian randomization-based approach to identify early and sensitive diagnostic biomarkers of disease. Clinical chemistry65, 427-436 (2019).
18 Ritchie, S. C. et al. Integrative analysis of the plasma proteome and polygenic risk of cardiometabolic diseases. BioRxiv (2019).
19 Speliotes, E. K. et al. Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. PLoS Genet7, e1001324 (2011).
20 Parisinos, C. A. et al. Genome-wide and Mendelian randomisation studies of liver MRI yield insights into the pathogenesis of steatohepatitis. Journal of hepatology73, 241-251 (2020).
21 Chambers, J. C. et al. Genome-wide association study identifies loci influencing concentrations of liver enzymes in plasma. Nature genetics43, 1131-1138 (2011).
22 Emdin, C. A. et al. A missense variant in Mitochondrial Amidoxime Reducing Component 1 gene and protection against liver disease. PLoS genetics16, e1008629 (2020).
23 Anstee, Q. M. et al. Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort☆. Journal of hepatology73, 505-515 (2020).
24 Mounier, N. & Kutalik, Z. bGWAS: an R package to perform Bayesian Genome Wide Association Studies. Bioinformatics (2020).
25 Liu, Z. et al. Causal relationships between NAFLD, T2D and obesity have implications for disease subphenotyping. Journal of Hepatology (2020).
26 Romeo, S. et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nature genetics40, 1461-1465 (2008).
27 Kozlitina, J. et al. Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease. Nature genetics46, 352-356 (2014).
28 Chen, V. L. et al. Genome-wide association study of serum liver enzymes implicates diverse metabolic and liver pathology. Nature communications12, 1-13 (2021).
29 Jamialahmadi, O. et al. Exome-Wide Association Study on Alanine Aminotransferase Identifies Sequence Variants in the GPAM and APOE Associated With Fatty Liver Disease. Gastroenterology (2021).
30 Richardson, K. et al. Gain-of-function lipoprotein lipase variant rs13702 modulates lipid traits through disruption of a microRNA-410 seed site. The American Journal of Human Genetics92, 5-14 (2013).
31 Consortium, G. The Genotype-Tissue Expression (GTEx) pilot analysis: Multitissue gene regulation in humans. Science348, 648-660 (2015).
32 Liu, B., Gloudemans, M. J., Rao, A. S., Ingelsson, E. & Montgomery, S. B. Abundant associations with gene expression complicate GWAS follow-up. Nature genetics51, 768-769 (2019).
33 Haas, M. E. et al. Machine learning enables new insights into clinical significance of and genetic contributions to liver fat accumulation. medRxiv (2020).
34 Kettunen, J. et al. Genome-wide study for circulating metabolites identifies 62 loci and reveals novel systemic effects of LPA. Nature communications7, 1-9 (2016).
35 Folkersen, L. et al. Mapping of 79 loci for 83 plasma protein biomarkers in cardiovascular disease. PLoS genetics13, e1006706 (2017).
36 Suhre, K. et al. Connecting genetic risk to disease end points through the human blood plasma proteome. Nature communications8, 1-14 (2017).
37 Sun, B. B. et al. Genomic atlas of the human plasma proteome. Nature558, 73-79 (2018).
38 Yao, C. et al. Genome‐wide mapping of plasma protein QTLs identifies putatively causal genes and pathways for cardiovascular disease. Nature communications9, 1-11 (2018).
39 Kamat, M. A. et al. PhenoScanner V2: an expanded tool for searching human genotype–phenotype associations. Bioinformatics35, 4851-4853 (2019).
40 Kryuchkova-Mostacci, N. & Robinson-Rechavi, M. A benchmark of gene expression tissue-specificity metrics. Briefings in bioinformatics18, 205-214 (2017).
41 Parisinos, C. A. et al. Genome-wide and Mendelian randomisation studies of liver MRI yield insights into the pathogenesis of steatohepatitis. Journal of Hepatology (2020).
42 Scuteri, A. et al. Genome-wide association scan shows genetic variants in the FTO gene are associated with obesity-related traits. PLoS Genet3, e115 (2007).
43 Genetics, M. I. & Investigators, C. E. C. Coding variation in ANGPTL4, LPL, and SVEP1 and the risk of coronary disease. The New England journal of medicine374, 1134 (2016).
44 Maltais, M., Brisson, D. & Gaudet, D. Non-Alcoholic Fatty Liver in Patients with Chylomicronemia. Journal of Clinical Medicine10, 669 (2021).
45 Grzych, G. et al. Plasma BCAA changes in Patients with NAFLD are Sex Dependent. The Journal of Clinical Endocrinology & Metabolism105, dgaa175 (2020).
46 Lovric, A. et al. Characterization of different fat depots in NAFLD using inflammation-associated proteome, lipidome and metabolome. Scientific reports8, 1-14 (2018).
47 Lim, S., Taskinen, M. R. & Borén, J. Crosstalk between nonalcoholic fatty liver disease and cardiometabolic syndrome. Obesity Reviews20, 599-611 (2019).
48 Jin, R. et al. Amino acid metabolism is altered in adolescents with nonalcoholic fatty liver disease—An untargeted, high resolution metabolomics study. The Journal of pediatrics172, 14-19. e15 (2016).
49 Lake, A. D. et al. Branched chain amino acid metabolism profiles in progressive human nonalcoholic fatty liver disease. Amino acids47, 603-615 (2015).
50 Sliz, E. et al. NAFLD risk alleles in PNPLA3, TM6SF2, GCKR and LYPLAL1 show divergent metabolic effects. Human molecular genetics27, 2214-2223 (2018).
51 Andersson, S. M., Salaspuro, M. & Ohisalo, J. J. Metabolic basis of hypertyrosinemia in liver disease. Gastroenterology82, 554-557 (1982).
52 Knapen, M. F. et al. Plasma glutathione S-transferase alpha 1-1: a more sensitive marker for hepatocellular damage than serum alanine aminotransferase in hypertensive disorders of pregnancy. American journal of obstetrics and gynecology178, 161-165 (1998).
53 Lieber, C. S. Metabolism of alcohol. Clinics in liver disease9, 1-35 (2005).
54 Männistö, V. T. et al. Ketone body production is differentially altered in steatosis and non‐alcoholic steatohepatitis in obese humans. Liver International35, 1853-1861 (2015).
55 Gaudet, D. et al. Vupanorsen, an N-acetyl galactosamine-conjugated antisense drug to ANGPTL3 mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyceridaemia. European heart journal41, 3936-3945 (2020).
56 Vergès, B. et al. Liraglutide Increases the Catabolism of Apolipoprotein B100–Containing Lipoproteins in Patients With Type 2 Diabetes and Reduces Proprotein Convertase Subtilisin/Kexin Type 9 Expression. Diabetes Care (2021).
57 Wilson, J. M. et al. The dual glucose‐dependent insulinotropic peptide and glucagon‐like peptide‐1 receptor agonist, tirzepatide, improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetes. Diabetes, Obesity and Metabolism22, 2451-2459 (2020).
58 Jongstra-Bilen, J. et al. Low-grade chronic inflammation in regions of the normal mouse arterial intima predisposed to atherosclerosis. 203, 2073-2083, doi:10.1084/jem.20060245 %J The Journal of Experimental Medicine (2006).
59 Namjou, B. et al. GWAS and enrichment analyses of non-alcoholic fatty liver disease identify new trait-associated genes and pathways across eMERGE Network. BMC medicine17, 135 (2019).
60 Willer, C. J., Li, Y. & Abecasis, G. R. METAL: fast and efficient meta-analysis of genomewide association scans. Bioinformatics26, 2190-2191 (2010).
61 Wright, F. A. et al. Heritability and genomics of gene expression in peripheral blood. Nature genetics46, 430-437 (2014).
62 Robinson, M. D. & Oshlack, A. A scaling normalization method for differential expression analysis of RNA-seq data. Genome biology11, 1-9 (2010).
63 Gamazon, E. R. et al. A gene-based association method for mapping traits using reference transcriptome data. Nature genetics47, 1091 (2015).
64 Barbeira, A. N. et al. Exploring the phenotypic consequences of tissue specific gene expression variation inferred from GWAS summary statistics. Nature communications9, 1-20 (2018).
65 Liu, B., Gloudemans, M. J., Rao, A. S., Ingelsson, E. & Montgomery, S. B. Abundant associations with gene expression complicate GWAS follow-up. Nat Genet51, 768-769, doi:10.1038/s41588-019-0404-0 (2019).
66 Karlson, E. W., Boutin, N. T., Hoffnagle, A. G. & Allen, N. L. Building the partners healthcare biobank at partners personalized medicine: informed consent, return of research results, recruitment lessons and operational considerations. Journal of personalized medicine6, 2 (2016).
67 Littlejohns, T. J. et al. The UK Biobank imaging enhancement of 100,000 participants: rationale, data collection, management and future directions. Nature Communications11, 1-12 (2020).
68 Bycroft, C. et al. The UK Biobank resource with deep phenotyping and genomic data. Nature562, 203-209 (2018).
69 Loh, P.-R. et al. Efficient Bayesian mixed-model analysis increases association power in large cohorts. Nature genetics47, 284 (2015).
70 Wilman, H. R. et al. Characterisation of liver fat in the UK Biobank cohort. PloS one12, e0172921 (2017).
71 Bowden, J. et al. A framework for the investigation of pleiotropy in two‐sample summary data Mendelian randomization. Statistics in medicine36, 1783-1802 (2017).
72 Verbanck, M., Chen, C.-y., Neale, B. & Do, R. Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases. Nature genetics50, 693-698 (2018).
73 Yanai, I. et al. Genome-wide midrange transcription profiles reveal expression level relationships in human tissue specification. Bioinformatics21, 650-659 (2005).
74 Zhou, W. et al. Efficiently controlling for case-control imbalance and sample relatedness in large-scale genetic association studies. Nature genetics50, 1335-1341 (2018).